新冠疫苗價格出來了!兩支不到千元,可100%保護
uSMART友信智投8月18日消息,新冠疫苗的時間表和價格區間出來了!
據光明日報消息,國藥集團黨委書記、董事長劉敬楨接受光明日報採訪時表示,國際臨床三期試驗結束後,新冠滅活疫苗就可以進入審批環節,預計今年12月底能夠上市。
預計北京生物製品研究所的滅活疫苗年產量能達1.2億劑,武漢生物製品研究所的滅活疫苗年產量能達1億劑。
另外,基因工程亞單位疫苗預計今年10月份能進入臨床研究,一旦研發成功後就能快速大規模量產。
此外,他還表示,兩針疫苗保護率達100%,價格不到1000元。
“新冠肺炎疫苗研究實際上有5個路線,即全病毒滅活疫苗、基因工程亞單位疫苗、腺病毒載體疫苗、減毒流感病毒載體疫苗,以及核酸疫苗。其中,核酸疫苗即mRNA和DNA疫苗。”劉敬楨介紹,疫情發生後,國藥集團集中精力在全病毒滅活疫苗和基因工程亞單位疫苗兩條路線上進行重點突破。
其中,國藥集團中國生物武漢生物製品研究所和北京生物製品研究所兩個單位在滅活疫苗路線上並行研究,國藥集團中國生物技術研究院則是在基因工程亞單位疫苗方面進行研究。
“滅活疫苗上市後,價格不會很高,預計幾百塊錢一針。如果打兩針的話,價格應在1000塊錢以內。”劉敬楨告訴記者,打一針疫苗,保護率大概是97%,抗體產生是緩慢的,像曲線一樣在緩慢增長,一般情況下大概半個月可以達到能抵抗新冠病毒的水準;如果打兩針疫苗,保護率能達到100%。
劉敬楨介紹,打第一針疫苗與第二針的時間間隔一般是28天,但特殊情況下可以同時打,左胳膊一針、右胳膊一針。一針疫苗劑量是4微克。
“我國14億人不是人人都有必要打,比如居住在人口密集城市的學生、上班族等是有必要的,而居住在人口稀少的農村地區的人們就可以不用打。”劉敬楨說。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.